Trial Profile

BEL116472. A 2 Year Mechanistic Study of Belimumab in Idiopathic Membranous Glomerulonephropathy

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 18 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Belimumab (Primary)
Indications Membranous glomerulonephritis
Focus Biomarker; Therapeutic Use
Sponsors GlaxoSmithKline; GSK

Most Recent Events

26 Jun 2019 Results of intent to treat population(n=14) and per protocol population (n=11) evaluating effect of belimumab on proteinuria published in the Nephrology Dialysis Transplantation
08 Nov 2016 Status changed from active, no longer recruiting to completed.
04 Sep 2016 Planned End Date changed from 1 Aug 2016 to 1 Sep 2016.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com